Last reviewed · How we verify
Triptorelin and recombinant FSH
At a glance
| Generic name | Triptorelin and recombinant FSH |
|---|---|
| Sponsor | Bioroma |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- Extra Luteinizing Hormone Improve Embryo Quality in IVF Patients With Low LH During Long GnRH-Agonist Treatment (NA)
- Cell-free DNA Analysis of Spent Embryo Culture Media as a Non-invasive Approach for Preimplantation Genetic Diagnosis
- Pregnancy and Neonatal Follow-up of Ongoing Pregnancies Established in Clinical Trial 38833 (P05783)
- Effect of GnRH Agonist Treatment Protocols on Ovarian Reserve (NA)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes. (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on Oocyte Morphology in Polycystic Ovary Syndrome Patients During IVF/ICSI (PHASE4)
- Effect of GnRH Agonist vs GnRH Antagonist on IVF/ICSI Outcomes in Polycystic Ovary Syndrome Patients. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Triptorelin and recombinant FSH CI brief — competitive landscape report
- Triptorelin and recombinant FSH updates RSS · CI watch RSS
- Bioroma portfolio CI